Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Study Meets Primary and Key Secondary Endpoints with High Statistical Significance
Statistically Significant Reduction of 62% and 70%
Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -
- Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -
finance.yahoo.com/news/immunic-inc-reports-positive-top-190000055.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1JTVVYJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAAA6N0afyvOGtkIasZaQBr1nGN86yGd-hjLGDX0B0KgNODvR_KhWRPk-Ao5Op-iaCFeErYM863SwP1L1ooEum5fr0veyleX6PZUJO5WTJRuqJm2ETwCipuNEAo-QhoN4Z08Xgi5Ja389VsNlp5YlR_NT-HiTUf_5qD8ew6PxYTuC2&_guc_consent_skip=1596537765
Study Meets Primary and Key Secondary Endpoints with High Statistical Significance
Statistically Significant Reduction of 62% and 70%
Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -
- Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -
finance.yahoo.com/news/immunic-inc-reports-positive-top-190000055.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1JTVVYJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAAA6N0afyvOGtkIasZaQBr1nGN86yGd-hjLGDX0B0KgNODvR_KhWRPk-Ao5Op-iaCFeErYM863SwP1L1ooEum5fr0veyleX6PZUJO5WTJRuqJm2ETwCipuNEAo-QhoN4Z08Xgi5Ja389VsNlp5YlR_NT-HiTUf_5qD8ew6PxYTuC2&_guc_consent_skip=1596537765
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.